Is Tarsons Products overvalued or undervalued?
2025-12-02 08:21:51Understanding Tarsons Products’ Valuation Metrics As of 1 December 2025, Tarsons Products exhibits a price-to-earnings (PE) ratio of 59.3, signalling a premium valuation relative to earnings. This is considerably higher than many of its peers, although some competitors in the healthcare services space command even loftier multiples. The price-to-book (P/B) ratio stands at 1.94, suggesting the stock trades nearly twice its book value, which is moderate but still indicative of investor confidence in the company’s asset utilisation. Enterprise value (EV) multiples further illustrate the valuation landscape. The EV to EBIT ratio is notably elevated at 40.7, while EV to EBITDA is 13.3, reflecting expectations of strong operational cash flow generation despite modest profita...
Read More
Tarsons Products Sees Revision in Market Evaluation Amidst Challenging Financial Trends
2025-11-30 10:24:23Tarsons Products, a small-cap player in the Healthcare Services sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability, rising leverage, and persistent underperformance relative to broader market benchmarks.
Read More
Tarsons Products Hits Intraday High with Strong 8.75% Surge
2025-11-25 13:52:23Tarsons Products demonstrated a robust intraday performance on 25 Nov 2025, surging to an intraday high of Rs 220.1, reflecting an 8.75% gain over the previous close. This notable uptick marks a reversal after a prolonged period of decline, positioning the stock as a standout performer within the Healthcare Services sector today.
Read More
Tarsons Products Hits Intraday Low Amid Price Pressure and Market Volatility
2025-11-24 14:18:36Tarsons Products experienced a significant intraday decline on 24 Nov 2025, touching a new 52-week and all-time low of ₹198.7. The stock faced notable price pressure, underperforming its sector and the broader market amid heightened volatility and a prolonged downward trend.
Read More
Tarsons Products Falls to 52-Week Low of Rs.198.7 Amid Prolonged Downtrend
2025-11-24 11:05:21Tarsons Products has reached a new 52-week low of Rs.198.7, marking a significant decline amid sustained downward pressure. The stock has experienced a continuous fall over the past 16 trading sessions, reflecting ongoing challenges within the healthcare services sector.
Read More
Tarsons Products Falls to 52-Week Low of Rs.198.7 Amid Prolonged Downtrend
2025-11-24 11:05:19Tarsons Products has reached a new 52-week low of Rs.198.7, marking a significant decline amid a sustained period of negative returns and heightened volatility. The stock’s recent performance contrasts sharply with broader market trends, underscoring ongoing challenges within the company’s financial metrics and market positioning.
Read More
Tarsons Products Falls to 52-Week Low of Rs.198.7 Amid Prolonged Downtrend
2025-11-24 11:05:19Tarsons Products, a player in the Healthcare Services sector, has reached a new 52-week low of Rs.198.7, marking a significant milestone in its ongoing price decline. The stock has experienced a sustained downward trajectory over the past several weeks, reflecting a series of financial and market challenges.
Read More
Tarsons Products Stock Falls to 52-Week Low of Rs.198.7 Amid Prolonged Downtrend
2025-11-24 11:05:19Tarsons Products has reached a new 52-week low of Rs.198.7 today, marking a significant decline amid a sustained downward trend that has extended over the past 16 trading sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the healthcare services sector.
Read More
Tarsons Products Falls to 52-Week Low of Rs.198.7 Amid Prolonged Downtrend
2025-11-24 11:05:17Tarsons Products, a key player in the Healthcare Services sector, has reached a new 52-week low of Rs.198.7, marking a significant decline amid a sustained downward trend. The stock has experienced a notable period of losses, reflecting ongoing pressures within the company’s financial performance and market positioning.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30-Jan-2026 | Source : BSEIntimation of Schedule of Investor/Analyst Conference Call to discuss the financial and operational performance for the quarter and nine months ended December 31 2025.
Board Meeting Intimation for The Quarter And Nine Months Ended December 31 2025
30-Jan-2026 | Source : BSETarsons Products Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
08-Jan-2026 | Source : BSECertificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2025
Corporate Actions
No Upcoming Board Meetings
Tarsons Products Ltd has declared 100% dividend, ex-date: 20 Sep 24
No Splits history available
No Bonus history available
No Rights history available